Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Results from Merck’s Vorinostat phase 1 trial on lymphoma

Patients whose aggressive lymphomas have relapsed or failed to respond to the current front-line chemotherapy regimen now have an effective second line of attack against their disease.

5 Feb 2013

PET with 11C-PIB can positively visualize amyloid deposits in the heart

While amyloid imaging may now be most associated with detecting plaques in the brain, it has the potential to change the way cardiac amyloidosis is diagnosed. According to first-of-its-kind research published in the February issue of The Journal of Nuclear Medicine, positron emission tomography (PET) with 11C-PIB can positively visualize amyloid deposits in the heart.

5 Feb 2013

Novian Health completes $11M funding round

Novian Health, developer of Novilase Breast Therapy, announced today that it has successfully completed a funding round totaling $11 million.

5 Feb 2013

Accumulation of passenger mutations can slow or even halt tumor growth

A typical cancer cell has thousands of mutations scattered throughout its genome and hundreds of mutated genes. However, only a handful of those genes, known as drivers, are responsible for cancerous traits such as uncontrolled growth. Cancer biologists have largely ignored the other mutations, believing they had little or no impact on cancer progression.

5 Feb 2013

FDA clears Ethicon Endo-Surgery’s ENSEAL G2 Articulating Tissue Sealer

To address surgeons' need for strong sealing in tight spaces where access is limited, Ethicon Endo-Surgery, Inc. (Ethicon) today announces the 510(k) clearance from the U.S. Food and Drug Administration for the ENSEAL G2 Articulating Tissue Sealer.

5 Feb 2013

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion

Gilead Sciences, Inc. announced today its results of operations for the fourth quarter and full year 2012.

5 Feb 2013

Oral toxicity is frequent limitation of mTOR therapy

Oral mucositis is a frequent complication in patients taking mTOR inhibitors and a major reason for dose reductions and discontinuations in clinical trials, according to a review of this class of cancer drugs.

4 Feb 2013

Hope against dangerous form of acute lymphoblastic leukemia

After an intensive three-year hunt through the genome, medical researchers have pinpointed mutations that leads to drug resistance and relapse in the most common type of childhood cancer-the first time anyone has linked the disease's reemergence to specific genetic anomalies.

4 Feb 2013

SIR, Society for Vascular Surgery partner on IVC filter study

The Society of Interventional Radiology and Society for Vascular Surgery jointly will launch PRESERVE-the first large-scale, multispecialty prospective study to evaluate the use of inferior vena cava (IVC) filters and related follow-up treatment.

2 Feb 2013

Scientists uncover key mechanism that links obesity and diabetes with cancer

Sugars are needed to provide us with energy and in moderate amounts contribute to our well-being. Sustained high levels of sugars, as is found in diabetics, damages our cells and now is shown that can also increase our chance to get cancer: The dose makes the poison as Paracelsus said.

1 Feb 2013

Seattle Genetics receives Health Canada approval for ADCETRIS to treat sALCL, Hodgkin lymphoma

Seattle Genetics, Inc. today announced that Health Canada has issued a Notice of Compliance with conditions (NOC/c), authorizing marketing of ADCETRIS for two lymphoma indications.

1 Feb 2013

Endothelial cells can trigger changes in cancer cells without direct contact

Blood vessels that supply oxygen and nutrients to tumors can also deliver something else - a signal that strengthens nearby cancer cells, making them more resistant to chemotherapy, more likely to spread to other organs and more lethal, scientists at The University of Texas MD Anderson Cancer Center report online in Cancer Cell.

1 Feb 2013

Weill Cornell and NewYork-Presbyterian create pioneering Institute for Precision Medicine

Recognizing that medicine is not "one size fits all," Weill Cornell Medical College and NewYork-Presbyterian Hospital have created the pioneering Institute for Precision Medicine at Weill Cornell and NewYork-Presbyterian/Weill Cornell Medical Center. This new, cutting-edge translational medicine research hub will explore the new frontier of precision medicine, offering optimal targeted, individualized treatment based on each patient's genetic profile.

1 Feb 2013

ArQule, Daiichi Sankyo initiate enrollment in tivantinib Phase 3 trial for hepatocellular carcinoma

Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the pivotal Phase 3 METIV-HCC (MET-high patients with tivantinib in HCC) trial of tivantinib (ARQ 197).

31 Jan 2013

Celsion's ThermoDox does not meet primary endpoint in Phase III HCC study

Celsion Corporation, a leading oncology drug development company, today announced that ThermoDox in combination with radiofrequency ablation (RFA) did not meet the primary endpoint of the Phase III HEAT Study in patients with hepatocellular carcinoma (HCC), also known as primary liver cancer.

31 Jan 2013

Cerulean initiates CRLX101 Phase 2 study in extensive-stage small cell lung cancer

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a randomized Phase 2 study of its lead candidate, CRLX101, in patients with extensive-stage small cell lung cancer (SCLC) sensitive to first-line platinum-based chemotherapy.

31 Jan 2013

Teva terminates collaboration with CureTech

Teva Pharmaceutical Industries Ltd. announced today the termination of its collaboration with CureTech Ltd.

31 Jan 2013

SGO proposes new ways to deliver high quality, cost-effective gynecologic cancer care

The Society of Gynecologic Oncology (SGO) today proposed new ways to deliver high quality, cost-effective care to women with gynecologic cancers.

31 Jan 2013

OncoEthix initiates OTX015 Phase I study in hematologic malignancies

OncoEthix, the Swiss-based specialist in oncology drug development, announces progress in its Phase I study of OTX015, a novel BET bromodomain inhibitor, with the first dosing of a patient.

31 Jan 2013

DSMB recommends continuation of CTI’s OPAXIO Phase 3 trial on ovarian cancer

Cell Therapeutics, Inc. (CTI) today announced that the Gynecologic Oncology Group (GOG) informed CTI that an independent Data Safety Monitoring Board (DSMB) recommended continuation of the GOG-0212 Phase 3 clinical trial of OPAXIOTM (paclitaxel poliglumex) as maintenance therapy in ovarian cancer with no changes following a planned interim survival analysis.

31 Jan 2013